Ebanks Brad, Chakrabarti Lisa
School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom.
MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Nottingham, United Kingdom.
Front Mol Biosci. 2022 Feb 14;9:854321. doi: 10.3389/fmolb.2022.854321. eCollection 2022.
The mitochondrial ATP synthase is responsible for the production of cellular ATP, and it does so by harnessing the membrane potential of the mitochondria that is produced by the sequential oxidation of select cellular metabolites. Since the structural features of ATP synthase were first resolved nearly three decades ago, significant progress has been made in understanding its role in health and disease. Mitochondrial dysfunction is common to neurodegeneration, with elevated oxidative stress a hallmark of this dysfunction. The patterns of this oxidative stress, including molecular targets and the form of oxidative modification, can vary widely. In this mini review we discuss the oxidative modifications of ATP synthase that have been observed in Alzheimer's disease, Parkinson's disease, and Huntington's disease. Oxidative modifications of ATP synthase in Alzheimer's disease are well-documented, and there is a growing body of knowledge on the subject in Parkinson's disease. The consideration of ATP synthase as a pharmacological target in a variety of diseases underlines the importance of understanding these modifications, both as a potential target, and also as inhibitors of any pharmacological intervention.
线粒体ATP合酶负责细胞ATP的产生,它通过利用线粒体的膜电位来实现这一功能,而线粒体膜电位是由特定细胞代谢物的顺序氧化产生的。自从大约三十年前首次解析出ATP合酶的结构特征以来,在理解其在健康和疾病中的作用方面已经取得了重大进展。线粒体功能障碍在神经退行性疾病中很常见,氧化应激升高是这种功能障碍的一个标志。这种氧化应激的模式,包括分子靶点和氧化修饰的形式,可能有很大差异。在这篇综述中,我们讨论了在阿尔茨海默病、帕金森病和亨廷顿病中观察到的ATP合酶的氧化修饰。阿尔茨海默病中ATP合酶的氧化修饰已有充分记录,帕金森病中关于这一主题的知识也在不断增加。将ATP合酶视为多种疾病的药理学靶点凸显了理解这些修饰的重要性,既是作为潜在靶点,也是作为任何药理学干预的抑制剂。